Prestige Consumer Healthcare (PBH) EBITDA (2010 - 2025)

Prestige Consumer Healthcare's EBITDA history runs 16 years deep, the most recent figure standing at $48.1 million for Q4 2025.

• In Q4 2025, EBITDA rose 1.39% year-over-year to $48.1 million; the TTM figure through Dec 2025 stood at $196.4 million (down 2.9% YoY), while the FY2025 annual figure was $211.4 million, up 2.44% from the prior year.
• EBITDA was $48.1 million for Q4 2025 at Prestige Consumer Healthcare, up from $42.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $60.5 million in Q4 2023 to a low of -$242.6 million in Q1 2023.
• Historically, EBITDA has averaged $35.3 million across 5 years, with a median of $50.6 million in 2021.
• The sharpest annual moves came in 2023 and 2024: EBITDA plunged 531.25% in 2023, then jumped 117.93% in 2024.
• A 5-year view of EBITDA shows it stood at $51.4 million in 2021, then rose by 14.57% to $58.9 million in 2022, then advanced by 2.7% to $60.5 million in 2023, then slipped by 21.66% to $47.4 million in 2024, then rose by 1.39% to $48.1 million in 2025.
• The last three EBITDA figures came in at $48.1 million (Q4 2025), $42.9 million (Q3 2025), and $52.9 million (Q2 2025), per Business Quant data.